In addition, multivariable analysis of a smaller cohort of intermediate-risk AML patients (defined by cytogenetics alone) identified ASXL1 and FLT3-ITD as factors predicting lower chances of achieving CR113. Here, ASXL1 is linked to acute myeloid leukemia.